Tarsus PharmaceuticalsTARS
Recorded

Tarsus Pharmaceuticals 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration50 minParticipants17

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, and welcome to Tarsus Pharmaceuticals' third quarter 2026 financial results conference call. As a reminder, this call is being recorded, and all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin. Thank you.

David NakasoneHead of Investor Relations

Before we begin, I encourage everyone to visit the investor section of the Tarsus website to view the press release issued today and related materials we will be discussing today. Joining me on the call today are Bobby Azamian, Chief Executive Officer and Chairman, Neera Clase, our Chief Commercial Officer, Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer. And joining us for Q&A is Dr. Liz Yeu, our Chief Medical Officer, and Sesha Neervannan, our Chief Operating Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details.

David NakasoneHead of Investor Relations

With that, I will turn the call over to Bobby.

Bobby AzamianCEO and Chairman

Good afternoon, and thank you for joining us. 1 million, 1 billion, five and five. More than 1 million bottles of XDEMVY dispensed, more than $1 billion in cumulative net product sales, and a pipeline with the potential to bring five new medicines to patients in the next five years. As we celebrate our 10th anniversary, those numbers say a lot about how far Tarsus has come. But what excites me the most is what they tell us about where we can go. We started with a conviction that there were important diseases in eye care hiding in plain sight, and that following the science to their root cause could lead to entirely new categories of medicine. XDEMVY showed what that conviction could accomplish. This quarter, we delivered record sales and are again raising our full-year outlook.

Bobby AzamianCEO and Chairman

Nira and Jeff will take you through the details and why we believe XDEMVY is just getting started. I want to talk about our broader ambition, building the next leader in eye care. Not one defined by a single drug, but by a repeatable ability to spot a disease the field has overlooked, bring forward a medicine that could change how it is treated, and bring it to patients. That is the standard we are applying across our pipeline. We want to be first or best, and we are choosing opportunities where we believe we can make a meaningful difference. With Stargardt disease, that means the potential to help children and young adults preserve vision they would otherwise lose. With IRX-101, it means improving antiseptic preparation for patients receiving repeated retinal injections.

Bobby AzamianCEO and Chairman

With our existing investigational programs for ocular rosacea and Lyme disease prevention, we have opportunities to address other diseases where patients still need better answers. Together, they give us what we believe is one of the most differentiated pipelines in eye care. Three years ago, we were launching a single product for a disease most people had never heard of. Today, we are a team that built the category from scratch, closed two acquisitions in two months, and is running several clinical programs. There was no playbook for any of it, so we wrote one, and the people who wrote it have grown with every chapter. Nira is a wonderful example. She joined us early in the Tarsus journey and started where it matters most, prioritizing patients can access and afford XDEMVY. That became the foundation for everything that followed.

Bobby AzamianCEO and Chairman

Since then, she has helped build the XDEMVY launch into one of the best in eye care, and I am very proud to have her as our Chief Commercial Officer. 1 million bottles shows what this team can do. $1 billion shows the model works. Five and five is what we plan to do next. Nira, over to you. Thank you, Bobby.

Neera ClaseChief Commercial Officer

I am honored to lead our commercial organization at such an important time for Tarsus. I know this business and this team well, and I have never been more confident in the opportunity ahead for XDEMVY. XDEMVY delivered another record quarter in Q3, approximately $195 million in net product sales, up nearly 64% year-over-year. We did it in a seasonally softer quarter when vacations and medical meetings mean fewer days in the office. Even so, weekly prescriptions of XDEMVY reached an all-time high, and that momentum has continued into the fourth quarter. There are three reinforcing pillars driving growth. One, increasing demand as more patients recognize their symptoms and ask about XDEMVY. Two, broader and deeper prescribing among our target eye care professionals, or ECPs. Three, a growing contribution from retreatments due to positive experiences from patients and their ECPs.

Neera ClaseChief Commercial Officer

The ongoing progress we are seeing on all three fronts reinforces our belief that we're still in the early phases of XDEMVY's growth trajectory. Let's begin with the new patient demand. The synergy between our branded advertising, John Cena campaign, and unbranded disease education efforts are helping more people recognize their symptoms and take action. What matters most isn't how many people see the campaign, it's what they do next. Patients are using our chat, taking the "You Might Be Right" quiz, and searching for a doctor, all signals that they intend to seek care. Those high-value actions grew 75% this quarter, and we're converting prescriptions at a higher rate than last year. That's why we're adding $5 million to our DTC spend, bringing our full-year investment to approximately $95 million, and we'll focus those dollars on the channels producing the strongest results.

Neera ClaseChief Commercial Officer

The second driver is ECP utilization, where prescribing is both deepening and broadening. In the third quarter, the number of ECPs writing at least five prescriptions per week, who we call daily prescribers, grew approximately 20% over the second quarter. That matters because it shows that screening and treatment for Demodex blepharitis, or DB, have become a routine part of their practices. Additionally, our growing body of real-world evidence is giving those ECPs more reasons to screen. At the recent American Academy of Optometry, or AAOpt meeting, we presented a chart review that identified DB in 91% of patients with recurrent chalazia or hordeola. Findings like these show ECPs where DB may be hiding in their practices and underscores their belief in the number of patients that could benefit from XDEMVY. The third driver is retreatment.

Neera ClaseChief Commercial Officer

This quarter, approximately 20% of prescriptions were for patients returning for another course of therapy, and we believe it will settle in the low 20% range over time. On a growing base of treated patients, that can become an increasingly meaningful and durable source of demand. Put together, new patient demand, broader and deeper ECP adoption, and retreatment show how durable the XDEMVY opportunity is. Approximately 25 million Americans are affected by DB. Even with more than 1 million bottles dispensed to date, we've reached only a fraction of the potential market. We're still building the category, expanding the disease recognition, and helping ECPs make DB screening a routine part of eye care. That progress reinforces our confidence in XDEMVY's potential to exceed $2 billion plus in peak annual sales and supports the increased full-year outlook Jeff will discuss next.

Neera ClaseChief Commercial Officer

To our commercial team, thank you for your discipline, urgency, and patient focus behind these results. You've built tremendous momentum, and we're energized for the opportunity ahead in 2027. Jeff, over to you for the financial results, updated guidance, and pipeline progress.

Jeff FarrowCFO and Chief Strategy Officer

Thanks, Nera. XDEMVY's continued growth is giving us greater opportunities to invest in Tarsus' future. Our job is to put that capital to work where it can create the greatest value, expanding XDEMVY's reach and advancing our pipeline through its next clinical milestones. We are making those decisions with discipline, directing commercial investments toward the opportunities generating the strongest returns, and planning development spending around advancing each of our programs. Starting with our third quarter results, we delivered XDEMVY net product sales of $194.6 million, driven by strong prescription volumes, gross margin of approximately 93%, and we ended the quarter with cash and cash equivalents of approximately $310 million. Turning to expenses, SG&A expense was $168 million.

Jeff FarrowCFO and Chief Strategy Officer

Excluding costs of the Alkeus acquisition, the year-over-year increase was primarily due to DTC and other promotional investments, our new key account leader team, and higher variable costs as XDEMVY volumes grew. R&D expense was $44 million for the quarter. Excluding costs of the Alkeus acquisition, the year-over-year increase was primarily due to TP-04, TP-05, IRX-101, and other ongoing programs. Acquired in-process research and development, or IPR&D charges, totaled $632 million, comprising $81 million for iRenix and $551 million for Alkeus. Additional details on the accounting for both transactions are available in our Form 10-Q issued earlier today. Now, turning to our updated full-year 2026 guidance, we expect our full-year 2026 XDEMVY sales outlook to be between $715 million to $730 million.

Jeff FarrowCFO and Chief Strategy Officer

The updated range reflects increased trends we are seeing in patient demand, deeper ECP utilization across multiple patient segments, and stronger returns from our DTC investment. It also accounted for the usual medical meetings and holidays that occur in the fourth quarter. Gross margin to remain steady at approximately 93%. SG&A expense of $605 million-$620 million, which includes stock compensation of $45 million-$50 million. This anticipated increase is due to higher variable fees driven by growing XDEMVY volumes, increased DTC investments, bringing our full-year spend to approximately $95 million, and integration costs related to Alkeus. An R&D expense of $140 million-$155 million, which includes stock compensation of $20 million-$25 million, reflecting progress across our clinical programs and the integration of the Alkeus and iRenix programs. Turning to our pipeline and international plans.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day